New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2013
10:16 EDTPIPPharmAthene says Army completed recombinant bioscavenger testing
PharmAthene announced that the U.S. Army Medical Research Institute for Chemical Defense has completed initial in vitro testing of the company's recombinant butyrylcholinesterase bioscavenger demonstrating that it successfully targets and binds to a broad spectrum of nerve agents, including sarin and tabun, which are believed to be part of the Syrian chemical weapons inventory.
News For PIP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:16 EDTPIPPharmAthene reports Valortim IDIQ contract fulfilled
PharmAthene announced that it has fulfilled its obligations under a fixed price, indefinite delivery, indefinite quantity, or IDIQ, contract, awarded in 2013 by the Biomedical Advanced Research and Development Authority for the company's anthrax anti-toxin, Valortim. Under the IDIQ contract, PharmAthene was selected to provide a specified quantity of its Valortim anthrax anti-toxin master cell bank for secure storage by the government as part of a risk mitigation strategy for anthrax medical countermeasures.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use